Year: 2022-23

Company: TLR Therapeutics (Fall Only)

Liaison(s): Israel Gutierrez

Development of a briefing book for a Type C meeting with the FDA regarding a Phase 2 multicenter study for the use of Tomolarimab in the treatment of myelodysplastic syndrome.